Katlyn Nemani, M.D.
Research Psychiatrist
Clinical Research
Dr. Katlyn Nemani is a clinical research psychiatrist at the Nathan Kline Institute and Research Assistant Professor of Psychiatry at the New York University School of Medicine. After earning her medical degree at Tufts University, she completed combined residency training in neurology and psychiatry at the NYU. Her goal is to advance and improve care for people with disorders at the interface of psychiatry and neurology with a cross-disciplinary approach. Prior to joining the Nathan Kline Institute she conducted clinical research at the Montreal Neurological Institute, Schizophrenia Research Program at Massachusetts General Hospital, and at NYU with mentorship from Dr. Donald Goff. Her research is focused on understanding the bidirectional relationship between systemic disease and psychopathology, particularly the interaction between the nervous system and immune system in people with psychosis.
During the COVID-19 pandemic Dr. Nemani completed several studies establishing schizophrenia as an independent risk factor for mortality among patients with COVID-19 infection. She is currently building upon this research to identify immune alterations in individuals with schizophrenia which may contribute to susceptibility to severe infection and symptoms of psychosis. Her current work is focused on examining immune responses to vaccination and autoantibody profiles in people with schizophrenia.
Select Publications
-
Nemani K, Williams SZ, Olfson M, Leckman-Westin E, Finnerty M, Kammer J, Smith TE, Silverman DJ, Lindenmayer JP, Capichioni G, Clelland J, Goff DC. Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State-wide Psychiatric Hospital System. JAMA Netw Open. 2022 May 2;5(5):e2210743. doi: 10.1001/jamanetworkopen.2022.10743. PMID: 35522282; PMCID: PMC9077485.
-
Nemani K, Conderino S, Marx J, Thorpe LE, Goff DC. Association Between Antipsychotic Use and COVID-19 Mortality Among People With Serious Mental Illness. JAMA Psychiatry. 2021 Sep 22. PMID: 34550323.
-
Nemani K, Li C, Olfson M, Blessing EM, Razavian N, Chen J, Petkova E, Goff DC. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. JAMA Psychiatry. 2021 Apr 1;78(4):380-386. PMID: 33502436; PMCID: PMC7841576.
-
Nemani K, Gurin L. Neuropsychiatric Complications after Stroke. Semin Neurol. 2021 Feb;41(1):85-100. PMID: 33511605.
-
Nemani KL, Greene MC, Ulloa M, Vincenzi B, Copeland PM, Al-Khadari S, Henderson DC. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clin Schizophr Relat Psychoses. 2019 Winter;12(4):168-176. PMID: 29164928; PMCID: PMC6489443.
-
Nemani K, Hosseini Ghomi R, McCormick B, Fan X. Schizophrenia and the gut-brain axis. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:155-60. PMID: 25240858.